ELB021 (anti-CD160 Oncology)

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

Tue, 07/18/2017 - 17:00

With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation im

ELSALYS BIOTECH expands its rights on CD160

Tue, 02/16/2016 - 17:00

Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an

ELSALYS BIOTECH acquires a first-in-class antibody with a dual biological mechanism of action: anti-angiogenic and immuno-modulator

Thu, 07/02/2015 - 17:00

Developed so far by MABLIFE in ophthalmology, the anti-CD160 antibody has also a significant therapeutic potential in oncology.

Contactez Nous

Headquarters, R&D, Shipping Address : ElsaLys Biotech SA, 317 Avenue Jean Jaurès, 69007 Lyon Administrative site : ElsaLys Biotech SA, Pépinière de Hautepierre 8 avenue Dante, CS 70033 F-67087 Strasbourg contact@elsalysbiotech.com +33 (0)4 37 28 73 00

ELB021 (anti-CD160 Oncology)

Catégories d'actualités

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation im

ELSALYS BIOTECH expands its rights on CD160

Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an

ELSALYS BIOTECH acquires a first-in-class antibody with a dual biological mechanism of action: anti-angiogenic and immuno-modulator

Developed so far by MABLIFE in ophthalmology, the anti-CD160 antibody has also a significant therapeutic potential in oncology.

Contactez Nous